Harbourvest Partners’s Century Therapeutics IPSC Stock Holding History

Harbourvest Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.1K	Hold	29,018	–	–	0.04%	6
2026 Q1	$65.6K	Hold	29,018	–	–	0.07%	5
2025 Q4	$28.9K	Hold	29,018	–	–	0.02%	7
2025 Q3	$14.5K	Hold	29,018	–	–	0.01%	9
2025 Q2	$16.2K	Hold	29,018	–	–	0.02%	15
2025 Q1	$13.8K	Hold	29,018	–	–	0.01%	15
2024 Q4	$29.3K	Hold	29,018	–	–	0.01%	21
2024 Q3	$49.6K	Hold	29,018	–	–	0.03%	28
2024 Q2	$74K	Hold	29,018	–	–	0.04%	32
2024 Q1	$121K	Hold	29,018	–	–	0.06%	40
2023 Q4	$96.3K	Hold	29,018	–	–	0.03%	46
2023 Q3	$58K	Hold	29,018	–	–	0.02%	54
2023 Q2	$91.7K	Hold	29,018	–	–	0.03%	54
2023 Q1	$101K	Hold	29,018	–	–	0.03%	55
2022 Q4	$149K	Hold	29,018	–	–	0.05%	56
2022 Q3	$287K	Buy	29,018 +14,387	+98%	+$152K	0.09%	54
2022 Q2	$123K	Hold	14,631	–	–	0.04%	58
2022 Q1	$184K	Hold	14,631	–	–	0.04%	62
2021 Q4	$232K	Buy	+14,631	New	+$275K	0.03%	59

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Harbourvest Partners's IPSC Position: Q2 2026 in Review

Harbourvest Partners held its Century Therapeutics (IPSC) position steady in Q2 2026 at 29,018 shares worth $71.1K. The position accounts for 0.04% of the portfolio, ranked #6.

Harbourvest Partners first reported a position in IPSC in Q4 2021 and has held it in 19 quarters since. The position peaked at $287K in Q3 2022. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Harbourvest Partners held 29,018 shares of Century Therapeutics worth $71.1K as of Q2 2026.
Harbourvest Partners left its Century Therapeutics share count unchanged in Q2 2026.
Century Therapeutics made up 0.04% of Harbourvest Partners's portfolio in Q2 2026, its #6 holding.
Harbourvest Partners first reported a position in Century Therapeutics in Q4 2021 and has held it in 19 quarters since.
Harbourvest Partners's Century Therapeutics position peaked at $287K in Q3 2022.
99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Harbourvest Partners's 13F filing for Q2 2026, filed 14 Aug 2026.